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The human immunodeficiency virus type 2 (HIV-2) strain ROD/B can efficiently use the 7tm chemokine
receptor CXCR-4 as a primary receptor to enter CD4-negative cells. We have stably expressed CXCR-4 on mink
lung Mv-1-lu and feline kidney CCC cells (normally restrictive to HIV entry) and have shown efficient fusion,
entry, and replication of ROD/B. Mutation of the two N-linked glycosylation sites on CXCR-4 (N113I, and
N1763Q) or pretreatment of CCC or Mv-1-lu cells expressing wild-type CXCR-4 with the glycosylation
inhibitor tunicamycin increased fusion and entry by ROD/B. Deletion of portions of the N terminus of CXCR-4
resulted in a 3- to 10-fold decrease in cell-free infection by ROD/B and complete inhibition of cell-cell fusion
by both ROD/B and another HIV-2 strain, CBL23. These data suggest that the N-terminal domain of CXCR-4
is involved in but is not essential for the efficient fusion of ROD/B with CD4-negative cells. Deletion of the
C-terminal (intracellular) domain of CXCR-4 did not significantly affect entry by ROD/B, indicating that
intracellular signalling through this domain does not play a significant role in entry by HIV-2.
Although CD4 is the primary receptor for the human and
simian immunodeficiency viruses (HIV-1, HIV-2, and SIV), it
is known that other cofactors are required for entry of these
viruses into target cells (5, 11, 24). The restriction to HIV-1
entry into certain CD4-positive cells is due to the absence of a
specific cofactor essential for fusion. Recently, two members of
the seven transmembrane (7tm) G-protein-coupled chemokine
receptor family of proteins, CXCR-4 (18) (also termed Fusin
or Lestr) and CCR-5, have been shown to function as core-
ceptors, together with CD4, for T-cell-line- and macrophage-
tropic HIV-1 isolates, respectively (1, 13, 15). Other members
of this family including CCR-3 and CCR-2b also act as cofac-
tors for some primary HIV-1 isolates (4, 14). The natural
ligands for some of these receptors block entry of HIV-1 (8, 15,
17, 28). Recent reports showing the formation of complexes
between gp120, CD4 and CXCR-4 (22) and evidence for direct
binding of gp120 to CCR-5 (37, 40) are beginning to give
insights into the mechanisms that HIV uses to fuse and enter
cells.
Several laboratories have shown that some HIV isolates can
infect lymphoid and nonlymphoid cells (6, 19, 25, 35, 36) in the
absence of CD4. Although infection in most of these examples
is extremely inefficient, the selection of an HIV-2 strain,
ROD/B (derived from the prototype HIV-2 strain ROD/A),
that can directly induce cell-cell fusion and efficient infection
of certain CD4-negative human cell lines has been reported
(6). The highly cytopathic nature of this infection indicates that
HIV-2 can efficiently utilize one or more alternate receptors
independently of CD4. ROD/B is able to use the 7tm chemo-
kine receptor CXCR-4 to efficiently enter CD4-negative cells
(16, 31). We also found that ROD/B can use CCR-3 and the
orphan receptor V28 to enter CCC cells but only after pre-
treatment of the virus with soluble CD4 (sCD4) (31).
In this article, we define some of the regions on CXCR-4
essential for the entry into CD4-negative cells by ROD/B.
Deletion of both the N terminus and C terminus and mutation
of the two N-linked glycosylation sites of CXCR-4 have been
studied for their ability to allow the entry of ROD/B into mink
(Mv-1-lu) and feline (CCC) cells.
MATERIALS AND METHODS
Cells. The human T-cell line H9 (30) was maintained as a suspension culture
in RPMI 1640 medium (Gibco), supplemented with 10% (vol/vol) fetal calf
serum (FCS), 60 mg of penicillin per ml, and 100 mg of streptomycin per ml. The
nonprimate lines, cat kidney CCC (10) and mink lung Mv-1-lu (20), were main-
tained as monolayers in Dulbecco’s modified Eagle’s medium (Gibco) supple-
mented with 5% (vol/vol) FCS, 60 mg of penicillin per ml, and 100 mg of
streptomycin per ml.
Viruses. The HIV-2 strain ROD/B (6) was derived from C8166 cells chroni-
cally infected with ROD/A (6). The HIV-2 strain CBL-23 has been described
previously (6).
Construction of plasmids. The construction of CXCR-4 N-terminal deletions
and point mutations (Table 1) is described elsewhere (29).
Transfection of cells. Six-well trays were seeded at 105 cells/well and incubated
overnight at 37°C. The cells were transfected with Lipofectamine (Gibco). Plas-
mid (1 mg) in 15 ml of phosphate-buffered saline (PBS) was mixed with 5 ml of
Lipofectamine diluted with 10 ml of PBS and was incubated for 30 min at room
temperature. The cells were washed twice with Optimem (Gibco) before being
overlaid with 800 ml of Optimem followed by the DNA-Lipofectamine com-
plexes. The cells were incubated for 5 h at 37°C and then washed with Optimem;
to each well was added 2 ml of Dulbecco’s modified Eagle’s medium (Gibco)
supplemented with 5% (vol/vol) FCS, 60 mg of penicillin per ml, and 100 mg of
streptomycin per ml. Stably transfected pools of cells were selected with 1 mg
(for CCC cells) or 2 mg (for Mv-1-lu cells) of G418 (Gibco) per ml 48 h
posttransfection. G418-resistant cells were usually obtained after 1 to 2 weeks of
selection.
Determination of cell surface expression of CXCR-4 constructs. Cell surface
expression of the CXCR-4 constructs was determined by fluorescence-activated
cell sorting (FACS). Approximately 106 CCC cells transfected with the different
CXCR-4 constructs were removed from the tissue culture dish with trypsin/
versene and washed with ice-cold PBS. The cells were resuspended in 100 ml of
PBS–1% FCS–0.1% sodium azide and incubated on ice for 20 min before being
centrifuged and resuspended in 50 ml of PBS–1% FCS–0.1% sodium azide
containing 5 mg of monoclonal antibody (MAb) 12G5 per ml (16). The cells were
incubated for 60 min at 20°C, washed twice in PBS–1% FCS–0.1% sodium azide,
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and resuspended in 50 ml of PBS–1% FCS–0.1% sodium azide containing fluo-
rescein isothiocyanate-conjugated goat anti-mouse antibody (Sera-labs) at a 1:40
dilution. After incubation for a further 60 min at 20°C, the cells were washed
three times in PBS–0.1% sodium azide and finally resuspended in 100 ml of
PBS–0.1% sodium azide and added to 300 ml of formol saline (4% formaldehyde
in 0.5% NaCl and 1.5% Na2SO4). They were then analyzed by FACS (Becton
Dickinson).
Cell-free virus infections. Virus supernatant stocks were serially diluted in
fivefold steps, and 250-ml aliquots were added to appropriate cell types in 24-well
trays. Unless otherwise stated, the virus was allowed to adsorb for 5 h at 37°C
before unbound virus was removed and replaced with appropriate medium. After
overnight incubation, 1 mg of azidothymidine (Sigma) per ml was added, and the
infected cells were immunostained after a further 3 to 5 days of incubation.
Cell-cell fusion assays. Cells transfected the CXCR-4 constructs were seeded
in 24-well trays at 2 3 105 cells per well and incubated overnight. H9 cells (106
per well) chronically infected with ROD/B were overlaid onto the cultures and
incubated for a further 24 h at 37°C. The cells were washed in PBS and fixed and
stained for 10 min in methanol containing 1% methylene blue and 0.25% basic
fuchsin. The cell layers were then washed with tap water and examined for
syncytia by low-power microscopy. An estimate of the percentage of nuclei
incorporated into syncytia in adherent cells was recorded (see Table 2).
Treatment of cells with tunicamycin. The cells were seeded at 105 cells/ml on
24-well trays and grown for 24 h at 37°C before medium containing 0.1 mg of
tunicamycin (Sigma) per ml was added. The cultures were allowed to grow for a
further 24 h before the medium was removed and fresh medium containing
serially diluted virus was added. The virus was allowed to adsorb for 5 h at 37°C,
when it was replaced with more fresh medium. After overnight incubation, 1 mg
of azidothymidine per ml was added, and the infected cells were immunostained
after a further 3-day incubation.
Immunostaining HIV-2-infected cells. Infection assays were typically per-
formed in 24-well tissue culture trays. At 3 days after infection, the medium was
removed and the cells were washed twice in PBS and fixed with a 50:50 mixture
of methanol-acetone at 240°C for 2 min. After removal of the methanol-ace-
tone, the cells were washed once with PBS followed by PBS containing 1%
(vol/vol) FCS. The primary antibody (pooled rat MAbs against ROD/B envelope
[26]), 250 ml/well diluted 1:50 in PBS–1% FCS) was added to the fixed cells and
allowed to bind for 1 h at room temperature, and then the monolayer was washed
twice in PBS–1% FCS. Goat anti-rat immunoglobulin G–b-galactosidase conju-
gate (Sera-labs) at a dilution of 1:300 (in PBS–1% FCS) was added for 1 h at
room temperature, and then the monolayer was washed twice in serum-free PBS.
Approximately 500 ml of 5-bromo-4-chloro-3-b-D-galactopyranoside (X-Gal)
substrate (0.5 mg/ml) in PBS containing 3 mM potassium ferricyanide, 3 mM
potassium ferrocyanide, and 1 mM magnesium chloride was added to each well.
Infected cells stained blue within 1 to 2 h of the addition of substrate.
RESULTS
HIV-2 (ROD/B) uses the 7tm receptor CXCR-4 for efficient
entry into CD4-negative cells. Mink Mv-1-lu cells and feline
CCC cells were chosen to study the role of CXCR-4 as the
main CD4-independent receptor for ROD/B because they are
restrictive to entry but are permissive for replication of the
virus (25). The cells were stably transfected with a cDNA clone
of human CXCR-4 in the expression plasmid pCDNA3 (29)
and infected with ROD/B. Efficient entry into and infection of
both Mv-1-lu and CCC cells was observed, although the titer
obtained in Mv-1-lu cells expressing CXCR-4 was fivefold re-
duced compared with that in CCC cells expressing CXCR-4
(Fig. 1). A low level of infection (#10 focus-forming units per
ml) of untransfected Mv-1-lu or CCC cells by ROD/B or
CBL23 was consistently observed (Fig. 1). This infectivity was
neutralized with an HIV-2-neutralizing MAb (MAb 8e [refer-
ence 26 and data not shown]), suggesting that these HIV-2
strains are able to use (albeit inefficiently) a nonhuman ho-
molog of CXCR-4 present on Mv-1-lu or CCC cells.
Infection of CCC cells expressing CXCR-4 was blocked by 4
mg of 12G5 (MAb against human CXCR-4 [16, 27]) per ml but
was not blocked by up to 20 mg of an anti-CD4 MAb (Q4120)
per ml, further indicating that ROD/B is specifically using the
transfected human CXCR-4 to enter the CCC cells (Fig. 2).
Cell-cell fusion of H9 cells chronically infected with ROD/B
or CBL23 is mediated by CXCR-4. H9 cells chronically in-
fected with ROD/B efficiently fused with CCC cells transfected
with CXCR-4 but not with nontransfected CCC cells. Addition
of sCD4 (5 mg/ml) had little effect on the number or size of
syncytia observed. However, fusion of H9 cells chronically in-
fected with HIV-2 strain CBL23 with CXCR-4-transfected
CCC cells could be enhanced significantly by the addition of
sCD4 (Table 2).
Infection of Mv-1-lu or CCC cells expressing CXCR-4 is
enhanced by pretreatment of the cells with tunicamycin. Treat-
ment of mink Mv-1-lu or feline CCC cells expressing human
CXCR-4 with the glycosylation inhibitor tunicamycin in-
creased the apparent titer of ROD/B by 10- and 2-fold, respec-
tively (Fig. 3a). Tunicamycin inhibits the first reaction in the
lipid-saccharide pathway, blocking N-linked glycosylation com-
pletely (34). We have shown previously that treatment of a
FIG. 1. Cell-free infection titers of ROD/B and CBL23 on CCC or Mv-1-lu
cells expressing human CXCR-4, in the presence or absence of sCD4 (5 mg/ml).
The titers are expressed as focus-forming units per milliliter.
FIG. 2. Infection of CCC cells expressing CXCR-4 by ROD/B in the pres-
ence of increasing concentrations of the anti-CXCR-4 MAb 12G5 (16) or the
anti-CD4 MAb Q4120 (MRC AIDS reagent program no. ARP318).
TABLE 1. Sequences of N-terminal deletions of CXCR-4a
Protein Sequence
CXCR-4 MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKiflptiysiifltg
N1 MSDNYTEEMGSGDYDSMKEPCFREENANFNKiflptiysiifltg
N2 MGSGDYDSMKEPCFREENANFNKiflptiysiifltg
N3 MKEPCFREENANFNKiflptiysiifltg
a The extracellular domain is shown in capital letters, and the first putative
transmembrane domain is shown in lowercase letters. The putative N-linked
glycosylation site in the N-terminal domain is highlighted in boldface type.
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variety of CD4-negative human cells with tunicamycin removes
the block to infection by ROD/B and postulated that differ-
ences in the complexity of glycosylation on these different cells
were at least partially responsible for the cell tropism pattern
of ROD/B on CD4-negative cells (35). The observation that
infection of Mv-1-lu and CCC cells expressing CXCR-4 can
also be enhanced after inhibition of glycosylation in these non-
primate cells suggests that the presence of complex glycans
interferes either with the binding of ROD/B to CXCR-4 or
with a postbinding fusion step. To investigate this further, we
mutated the two potential N-linked glycosylation sites on
CXCR-4.
Mutation of the N-linked glycosylation sites on CXCR-4
increases the efficiency of entry of ROD/B. The two potential
N-linked glycosylation sites on CXCR-4 (one in the N-terminal
domain and the other in the second extracellular loop) were
mutated by site-directed mutagenesis (two single mutants, G1
[N113I] and G2 [N1763Q], and a double mutant, G1G2
[N113I, N1763Q]). At least one of these sites has been shown
to be glycosylated (2). Upon transfection of either the single
mutants (G1 or G2) or the double mutant (G1G2), ROD/B
infection of CCC cells was enhanced twofold in comparison
with wild-type (wt) CXCR-4 (Fig. 3b). These data are compat-
ible with the previous results obtained by treating cells with
tunicamycin (35). Cell surface expression of the glycosylation
mutants was calculated at between 37 and 52% of wt CXCR-4
(as determined by FACS with the CXCR-4-specific MAb 12G5
[16] [Table 2]), suggesting that the increase in ROD/B infec-
tion is specific to the lack of carbohydrate rather than being
caused by an increase in cell surface expression. In addition to
enhanced cell-free infection, an increase in cell-cell fusion by
ROD/B was also observed with CCC cells expressing these
glycosylation mutants (Table 2). However, no enhancement of
cell fusion by CBL23 was observed with the glycosylation mu-
tants (Table 2).
N-terminal deletions of CXCR-4 interfere with cell fusion
but not cell-free infection by ROD/B. The enhancement of
infection by ROD/B upon mutation of an N-linked glycosyla-
tion site in the N-terminal domain suggested either that part of
the envelope binding determinant is defined by this region of
CXCR-4 or that this domain is involved in the fusion process.
We therefore tested a set of deletions covering the N-terminal
(extracellular) domain of CXCR-4 (29) to determine the role
of this domain in the fusion of HIV-2. Although expression of
these deletions in CCC cells led to a decrease (3- to 10-fold) in
the cell-free infection by ROD/B (Fig. 4), infection signifi-
cantly above the control transfection was still observed. How-
ever, fusion of CCC cells expressing these N-terminal deletions
FIG. 3. (a) ROD/B cell-free infection of CCC or Mv-1-lu cells expressing
human CXCR-4 is enhanced by pretreatment of the cells with the glycosylation
inhibitor tunicamycin. (b) ROD/B cell-free infection of CCC cells expressing
human CXCR-4 or N-linked glycosylation mutants of CXCR-4. Two single
mutants, G1 (N113I) and G2 (N1763Q), and a double mutant, G1G2 (N113I;
N1763Q), were used.
FIG. 4. ROD/B cell-free infection of CCC cells expressing human CXCR-4 or
N-terminal deletions (Table 1) or a C-terminal deletion (DK3103S352) of CXCR-4.
TABLE 2. Cell-cell fusion of chronically infected H9 cells with
CCC cells expressing various CXCR-4 deletions and mutants
Protein
Syncytium formation bya:
% Surface
expressionbROD/B CBL23
2sCD4 1sCD4 2sCD4 1sCD4
CXCR-4 111 1111 1 111 100
N1 6 6 2 2 100
N2 2 2 2 2 13
N3 2 2 2 2 7
G1 1111 1111 1 11 37
G2 1111 1111 1 11 48
G1G2 1111 1111 1 11 52
C1 11 111 1 11 57
a An estimate of the percentage of nuclei incorporated into syncytia in adher-
ent cells was recorded as follows: 2, ,2%; 1, 2 to 5%; 11, 5 to 20%; 111, 20
to 50%; 1111, .50%.
b Surface expression of the different CXCR-4 constructs was determined by
FACS with the CXCR-4-specific MAb 12G5 (16). Surface expression levels of
the CXCR-4 mutants were calculated from the median immunofluorescence
values and are shown as a percentage of the level for wt CXCR-4.
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with H9 cells chronically infected with either ROD/B or
CBL23 was almost completely blocked (Fig. 5; Table 2). The
block to fusion imposed by deletion of parts of the N terminus
could not be relieved by the addition of sCD4 to the medium.
Cell surface expression of the N-terminal deletions of
CXCR-4 (Table 2), determined by FACS with the CXCR-4-
specific MAb 12G5 (16), revealed that N1 was expressed at
identical levels to that of CXCR-4 but N2 and N3 were poorly
expressed on the cell surface (13 and 7% of CXCR-4 levels,
respectively). The lower level of cell surface expression of the
two longest N-terminal deletions (N2 and N3) compared with
CXCR-4 could explain the lack of cell-cell fusion, which may
rely on high levels of expressed receptor to proceed efficiently.
However, the cell surface expression of N1 was identical to that
of CXCR-4 but cell-cell fusion was still greatly impaired, sug-
gesting that fusion requires an intact N terminus to proceed
efficiently.
The fact that cell-cell but not cell-free fusion is blocked
suggests that there are distinct requirements for these two
processes and that the N terminus of CXCR-4 is involved in
the fusion reaction.
Deletion of the C terminus of CXCR-4 has no effect on
infection by ROD/B. The C-terminal domain of CXCR-4 is
potentially involved in the transmission of intracellular signals
in response to binding of its chemokine ligand (SDF-1) at the
cell surface (3, 28). Deletion of this domain (C1; DK3103S352)
had little effect on the ability of ROD/B to use this construct as
a receptor for fusion and entry (Fig. 4), suggesting that intra-
cellular signalling through this domain is not involved in the
process of viral entry. However, we cannot rule out the impor-
tance of signalling through the other intracellular loops in the
entry and fusion process of HIV-2.
DISCUSSION
The HIV-2 strain ROD/B is able to efficiently enter a variety
of CD4-negative human cells (6, 35). We have investigated
several features of the 7tm chemokine receptor CXCR-4 which
are important for its role as a primary receptor for HIV-2
strain ROD/B in the absence of CD4. Expression of a cDNA
clone of human CXCR-4 in feline CCC or mink Mv-1-lu cells
enabled the efficient CD4-independent fusion and entry of
ROD/B into these cells, which are normally refractory to HIV
entry. The mutations in the ROD/B envelope (SU and TM)
which are responsible for its CD4-independent phenotype (32)
have recently been mapped. One amino acid change that sig-
nificantly enhances a minimal CD4-independent phenotype is
in the V3 loop. The V3 loop is the primary tropism determi-
nant in the HIV envelope and is a common target of neutral-
izing antibodies although it is not involved in the interaction of
the envelope with CD4. Choe et al. (4) have recently mapped
a determinant for coreceptor utilization to the V3 loop of the
HIV-1 gp120 surface envelope glycoprotein, and others (37,
40) have shown that antibodies to the V3 loop can block the
interaction of gp120 with CCR-5. It has been proposed that
CD4-dependent strains of HIV need an initial interaction with
CD4 to induce conformational changes within the envelope
which are essential for the subsequent fusion event involving
7tm membrane proteins (13–15, 18). This is apparently the
case with HIV-2 strains such as CBL23 which are able to fuse
FIG. 5. Cell-cell fusion of CCC cells expressing CXCR-4, N-terminal deletion N1, or glycosylation mutant G1 with H9 cells (black spheres in the photographs)
chronically infected with ROD/B or CBL23.
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with CD4-negative cells (such as CCC cells expressing CXCR-
4) only after activation of the envelope with sCD4. The muta-
tions in the ROD/B envelope could remove the necessity for
CD4 by lowering the activation threshold required for trigger-
ing conformational changes in the envelope glycoproteins that
lead to fusion or by increasing the affinity of the interaction of
the envelope SU with the 7tm receptor.
We have shown previously that a block to ROD/B entry into
certain human CD4-negative cells could be removed by pre-
treating cells with the glycosylation inhibitor tunicamycin (35).
Tunicamycin inhibits the first reaction in the lipid-saccharide
pathway, blocking N-linked glycosylation completely (34). We
suggested that complex glycans that are present on the ROD/B
CD4-independent receptor and that probably vary among cell
types could sterically block the interaction with the ROD/B
envelope. Removal of these complex glycans would therefore
permit the necessary close interaction between the ROD/B
envelope and its primary receptor (CXCR-4). Pretreatment of
CCC or Mv-1-lu cells expressing human CXCR-4 (which has
been shown to be glycosylated [2]) with tunicamycin enhanced
infection by ROD/B. A greater enhancement was observed
with Mv-1-lu cells, presumably due to different glycosylation
patterns compared with CCC cells. To confirm that the ob-
served enhancement is due to a specific effect on CXCR-4 and
not simply to a general reduction in the amount of carbohy-
drate on the cell surface, we specifically mutated the two N-
linked glycosylation sites on CXCR-4 and expressed these mu-
tants in CCC cells. A similar enhancement of both fusion and
infection of these cells by ROD/B was observed in comparison
with wt CXCR-4, confirming that expression of complex gly-
cans on CXCR-4 can interfere with the interaction of the
ROD/B envelope. However, enhancement of fusion with an-
other HIV-2 strain (CBL23) or several HIV-1 strains (29) was
not observed when these glycosylation mutants were expressed
on CCC cells (or CCC-CD4 cells for HIV-1). These data sug-
gest that different HIV envelopes are able to interact differ-
ently with or recognize distinct domains of CXCR-4 during the
fusion process. Alternatively, the carbohydrates on CXCR-4
may interfere with regions of the ROD/B envelope distal to the
receptor binding domain.
The fact that the N-terminal domains of both CXC and CC
chemokine receptors contain the primary high-affinity binding
site for chemokine ligands (38) and that these ligands can
block HIV-1 infection (3, 8, 15, 28) suggest that this domain
may be important for binding or entry of the virus. Deletion of
portions of the N-terminal domain of CXCR-4 had a negative
effect on cell-free infection by ROD/B, although infection sig-
nificantly above background levels was still observed even with
the longest deletion. Although N-terminal deletions of CXCR-
4 can still function as a receptor for ROD/B, cell-cell fusion
and syncytium formation were blocked. Fusion of these CXCR-4
deletions with ROD/B- or CBL23-chronically infected H9 cells
could not be rescued by addition of sCD4 to the medium.
These data suggest that although the N-terminal domain of
CXCR-4 is not essential for infection, it may play a role in
enhancing or modulating the fusion process with these viruses,
perhaps by affecting the triggering of gp41 exposure. We have
shown that N-terminal deletions of CXCR-4 can block infec-
tion by some HIV-1 strains but have little or no effect on the
entry of others (29) and that inhibition of HIV fusion by a
MAb to CXCR-4 (12G5 [16]) is both cell type and virus strain
dependent (27). These data imply that the site of interaction
on CXCR-4 varies among different strains of HIV. In contrast
to the data showing that the N-terminal domain of CXCR-4 is
not essential for HIV entry, Rucker et al. (33) have shown that
the N-terminal domain of CCR-5 is important for determining
coreceptor specificity for HIV-1.
It is becoming increasingly clear that different strains of
HIV-1 and HIV-2 can use divergent members of the 7tm re-
ceptor family (1, 4, 13–15, 18, 31). It has also been suggested
that there are differences in how these 7tm receptors are used
by different isolates and that these interactions are conforma-
tionally complex (27, 33). It appears that strains of HIV-2, in
particular, are able to use a larger repertoire of 7tm receptors
both as coreceptors (with CD4 [24a]) and as primary receptors
(31). The analysis of the fusion mechanism mediated by 7tm
molecules may benefit from the use of HIV strains such as
ROD/B, which are capable of using 7tm molecules to enter
cells efficiently in the absence of CD4 (31). It still remains to be
shown whether the use of 7tm receptors as primary receptors
in the absence of CD4 has relevance for the pathogenesis of
HIV in vivo. However, there is evidence for the productive
infection of cells that are apparently CD4 negative in tissues
from HIV-infected humans (9, 12, 21, 23, 39). The ability of
HIV-2 to utilize divergent members of the family of 7tm re-
ceptors (with CXCR-4 being used efficiently in the absence of
CD4) may have important implications for infection of the
immune, heamatopoietic, and/or nervous systems in the natu-
ral history of infection by HIV-2.
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